Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

Key Points

• Royal Bank of Canada lowered BioCryst’s price target from $14 to $13 while maintaining an “outperform” rating, implying approximately 38% upside from the prior close.
• Analyst sentiment remains broadly positive: eight analysts rate the stock a Buy and four a Hold, producing a “Moderate Buy” consensus and an average target price of $20.60.
• BioCryst exceeded quarterly expectations, reporting $0.30 in EPS versus a $0.15 consensus and revenue of $218.25 million, up 33.6% year over year; however, analysts still expect a full-year loss and the company continues to post negative profitability metrics.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its price target lowered by equities researchers at Royal Bank Of Canada from $14.00 to $13.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the biotechnology company's stock. Royal Bank Of Canada's price target suggests a potential upside of 37.99% from the company's previous close.

Several other research firms have also recently weighed in on BCRX. Weiss Ratings reaffirmed a "hold (c)" rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Wedbush lowered their price target on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating for the company in a research report on Thursday. Citizens Jmp boosted their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a "market outperform" rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. started coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They issued a "neutral" rating and a $12.00 price target on the stock. Finally, Cantor Fitzgerald raised their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an "overweight" rating in a report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $20.60.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded up $0.35 during trading hours on Thursday, reaching $9.42. 1,585,365 shares of the company's stock traded hands, compared to its average volume of 4,986,546. The firm has a 50-day simple moving average of $9.32 and a 200 day simple moving average of $8.69. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.22. The firm has a market cap of $2.39 billion, a PE ratio of -5.29 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analysts' expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.BioCryst Pharmaceuticals's revenue was up 33.6% compared to the same quarter last year. During the same period last year, the firm posted $0.15 earnings per share. Sell-side analysts forecast that BioCryst Pharmaceuticals will post -2.58 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. State of Wyoming acquired a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $583,000. GSA Capital Partners LLP bought a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth about $902,000. Wedge Capital Management L L P NC bought a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $3,808,000. Assenagon Asset Management S.A. lifted its position in shares of BioCryst Pharmaceuticals by 51.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 353,044 shares of the biotechnology company's stock worth $3,530,000 after buying an additional 120,097 shares during the last quarter. Finally, Pacer Advisors Inc. bought a new position in BioCryst Pharmaceuticals in the first quarter worth about $14,880,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

More BioCryst Pharmaceuticals News

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q2 results exceeded expectations: BioCryst reported adjusted earnings of $0.30 per share, versus the $0.14–$0.15 analyst consensus, while revenue rose 33.6% year over year to $218.3 million, well above estimates of approximately $183.3 million. BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised
• Positive Sentiment: Revenue outlook was raised: Management increased 2026 total revenue guidance to $690 million–$715 million, while maintaining ORLADEYO revenue guidance of $625 million–$645 million. ORLADEYO generated $158.2 million in second-quarter revenue, reinforcing the drug’s role as the company’s primary commercial growth driver. BioCryst Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Commercial and pipeline progress: BioCryst began shipping ORLADEYO oral pellets for pediatric patients on August 3 and completed enrollment in the pivotal ALPHA-ORBIT study of navenibart. These developments expand the potential patient base and provide an additional future growth opportunity. BioCryst Pharmaceuticals, Inc. 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Buyout speculation is unconfirmed: Retail investors have renewed acquisition speculation following the earnings beat and growing ORLADEYO sales, but no transaction or formal takeover interest was announced. BioCryst Bets on Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat
• Negative Sentiment: Profitability remains uneven: Despite reported operating profit, BioCryst continues to show a negative net margin and return on equity, and analysts still expect a full-year loss. Investors also remain dependent on continued ORLADEYO growth and successful development of navenibart.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source